1. Home
  2. INGN vs CBIO Comparison

INGN vs CBIO Comparison

Compare INGN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INGN
  • CBIO
  • Stock Information
  • Founded
  • INGN 2001
  • CBIO 2003
  • Country
  • INGN United States
  • CBIO United States
  • Employees
  • INGN N/A
  • CBIO N/A
  • Industry
  • INGN Industrial Specialties
  • CBIO
  • Sector
  • INGN Health Care
  • CBIO
  • Exchange
  • INGN Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • INGN 186.8M
  • CBIO 219.5M
  • IPO Year
  • INGN 2014
  • CBIO N/A
  • Fundamental
  • Price
  • INGN $7.02
  • CBIO $15.07
  • Analyst Decision
  • INGN Strong Buy
  • CBIO Strong Buy
  • Analyst Count
  • INGN 3
  • CBIO 5
  • Target Price
  • INGN $11.00
  • CBIO $25.60
  • AVG Volume (30 Days)
  • INGN 210.9K
  • CBIO 61.7K
  • Earning Date
  • INGN 11-05-2025
  • CBIO 11-06-2025
  • Dividend Yield
  • INGN N/A
  • CBIO N/A
  • EPS Growth
  • INGN N/A
  • CBIO N/A
  • EPS
  • INGN N/A
  • CBIO N/A
  • Revenue
  • INGN $347,028,000.00
  • CBIO N/A
  • Revenue This Year
  • INGN $8.12
  • CBIO N/A
  • Revenue Next Year
  • INGN $9.02
  • CBIO N/A
  • P/E Ratio
  • INGN N/A
  • CBIO N/A
  • Revenue Growth
  • INGN 4.68
  • CBIO N/A
  • 52 Week Low
  • INGN $5.70
  • CBIO $9.81
  • 52 Week High
  • INGN $12.91
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • INGN 41.91
  • CBIO 72.03
  • Support Level
  • INGN $6.92
  • CBIO $12.76
  • Resistance Level
  • INGN $7.20
  • CBIO $15.40
  • Average True Range (ATR)
  • INGN 0.27
  • CBIO 0.60
  • MACD
  • INGN 0.05
  • CBIO 0.19
  • Stochastic Oscillator
  • INGN 74.07
  • CBIO 78.64

About INGN Inogen Inc

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: